KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Dynavax Technologies (DVAX) Raw Materials (2018 - 2024)

Historic Raw Materials for Dynavax Technologies (DVAX) over the last 7 years, with Q2 2024 value amounting to $24.1 million.

  • Dynavax Technologies' Raw Materials rose 324.76% to $24.1 million in Q2 2024 from the same period last year, while for Jun 2024 it was $24.1 million, marking a year-over-year increase of 324.76%. This contributed to the annual value of $27.3 million for FY2023, which is 681.51% up from last year.
  • Dynavax Technologies' Raw Materials amounted to $24.1 million in Q2 2024, which was up 324.76% from $19.7 million recorded in Q1 2024.
  • In the past 5 years, Dynavax Technologies' Raw Materials ranged from a high of $32.8 million in Q2 2022 and a low of $18.4 million during Q1 2020
  • Its 5-year average for Raw Materials is $25.5 million, with a median of $25.3 million in 2021.
  • As far as peak fluctuations go, Dynavax Technologies' Raw Materials surged by 6529.15% in 2020, and later crashed by 2872.3% in 2023.
  • Over the past 5 years, Dynavax Technologies' Raw Materials (Quarter) stood at $25.1 million in 2020, then increased by 6.03% to $26.6 million in 2021, then fell by 4.2% to $25.5 million in 2022, then increased by 6.82% to $27.3 million in 2023, then dropped by 11.47% to $24.1 million in 2024.
  • Its Raw Materials stands at $24.1 million for Q2 2024, versus $19.7 million for Q1 2024 and $27.3 million for Q4 2023.